Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

115.23
+0.49000.43%
Post-market: 115.690.4600+0.40%19:50 EDT
Volume:910.31K
Turnover:105.35M
Market Cap:12.46B
PE:254.00
High:118.07
Open:114.80
Low:113.98
Close:114.74
52wk High:126.38
52wk Low:28.66
Shares:108.10M
Float Shares:96.44M
Volume Ratio:0.97
T/O Rate:0.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4537
EPS(LYR):0.8200
ROE:8.23%
ROA:0.47%
PB:17.65
PE(LYR):140.52

Loading ...

Corcept Therapeutics (CORT) Stock Could Trade At A Discount As Its 346% Run Looms

Simply Wall St.
·
Jul 18

Corcept Therapeutics CFO Atabak Mokari Disposes of 40,000 Common Shares for $3.52 Million

Reuters
·
Jul 18

Is Corcept Therapeutics (CORT) Fully Valued On Its Russell Index Removal?

Simply Wall St.
·
Jul 10

Corcept Chief Development Officer William Guyer Disposes of USD 1.87 Million in Common Shares

Reuters
·
Jul 09

Corcept Endocrinology President Sean Maduck Sells USD 2.19 Million of Corcept Therapeutics Shares

Reuters
·
Jul 07

Does Corcept’s Exit From Russell Defensive Indexes Reframe Its Risk Profile And Investor Base (CORT)?

Simply Wall St.
·
Jul 05

Is Corcept Therapeutics (CORT) Undervalued On Its Russell Index Removal?

Simply Wall St.
·
Jul 02

Corcept Therapeutics Rocked by Major Insider Stock Sale

TIPRANKS
·
Jun 19

Corcept director David Mahoney disposes of 20,000 shares worth $1.69 million

Reuters
·
Jun 19

Corcept Therapeutics (CORT) Stock After 114% YTD Surge Is The Rally Justified

Simply Wall St.
·
Jun 18

Corcept CFO Atabak Mokari sells common shares worth $3.22 million

Reuters
·
Jun 18

Corcept Therapeutics resubmits NDA for Relacorilant in Cushing’s Syndrome

TIPRANKS
·
Jun 18

Corcept resubmits FDA NDA for relacorilant in Cushing’s syndrome, expects six-month review

Reuters
·
Jun 18

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients With Cushing’s Syndrome

THOMSON REUTERS
·
Jun 18

Corcept Therapeutics - Resubmission Includes Additional Analyses; Expects Six-Month FDA Review

THOMSON REUTERS
·
Jun 18

Corcept Therapeutics (CORT) Valuation After New Korlym CATALYST And MOMENTUM Trial Data

Simply Wall St.
·
Jun 10

Corcept announces presentation of new data from Catalyst, Momentum trials

TIPRANKS
·
Jun 08

Lifyorli Survival Data and DOJ Update Might Change The Case For Investing In Corcept Therapeutics (CORT)

Simply Wall St.
·
Jun 07

Corcept Chief Development Officer William Guyer disposes of 20,000 common shares for $1.41 million

Reuters
·
Jun 05

Corcept Endocrinology President Sean Maduck disposes of Corcept Therapeutics shares worth $1.75 million

Reuters
·
Jun 04